New drug targets Hard-to-Treat cancers with PTEN mutation
NCT ID NCT04439149
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a drug called GSK2636771 in 24 patients whose advanced cancers have a PTEN mutation or deletion. The drug blocks a protein (PI3K-beta) that may help these cancer cells grow. Researchers want to see if the drug can shrink tumors or stop them from growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- GSK2636771 (a PI3K-beta inhibitor drug)
- What this could lead to
- If it works, this could point toward a targeted treatment option for cancers with PTEN mutations or deletions.
- What could go wrong
- This is a small, early-phase trial with only 24 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a new PET tracer reveal hidden immune clues in tumors?
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a protein calm the immune System's overreaction to cancer treatment?
- A hug in a blanket: could deep pressure calm cancer infusion anxiety?
- Could a strong social circle turn back the clock for transplant survivors?